+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the efficacy and safety of orforglipron in adults with overweight who are at risk of developing obesity-related complications such as type 2 diabetes, hypertension, and dyslipidemia, or progressing to class 1 obesity. The study is a phase 3, randomized, double-blind, placebo-controlled trial that aims to understand whether this oral medication can reduce these risks over a two-year period. Participants will be randomly assigned to one of three groups receiving orforglipron orally throughout, orforglipron followed by placebo, or placebo followed by orforglipron. The study involves daily oral administration of these medications. The trial includes a long-term treatment period lasting up to 104 weeks about two years, during which participants are monitored for weight changes and the onset of obesity-related health issues. Throughout the study, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood markers like glycated hemoglobin and triglycerides, and quality of life questionnaires. Researchers will also monitor the time to onset of obesity-related complications and pharmacokinetics of orforglipron at specified intervals. Safety and effectiveness will be tracked continuously, with the primary outcome being the time until the development of obesity-related complications or progression to class 1 obesity.

Age: 18Years +All GendersPhase 3
180 locations